PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104604
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104604
Preimplantation Genetic Testing Market size was valued at US$ 830.4 Million in 2025, expanding at a CAGR of 9.8% from 2026 to 2033.
The Preimplantation Genetic Testing (PGT) Market includes the use of technologies for genetic testing that help screen the embryos that are produced via in vitro fertilization (IVF) in order to detect chromosomal anomalies, inheritable genetic disorders, and chromosome rearrangement. Preimplantation Genetic Testing (PGT) allows selecting healthy embryos from a genetic standpoint, thus boosting the chances of IVF success while minimizing the risks of transmission of genetic disorders and fetal losses.
The market demonstrates rapid growth due to the growing incidence of genetic disorders, increasing infertility levels, growing age of women, and the adoption of ART procedures. The advances in next generation sequencing (NGS), polymerase chain reaction (PCR), and microarray technologies help boost the effectiveness of the embryo screening. Moreover, growing awareness of reproductive genetics, government support for fertility treatments, and investments in precision medicine should contribute to the further growth of the global Preimplantation Genetic Testing Market.
Preimplantation Genetic Testing Market- Market Dynamics
Rising Utilization of Assisted Reproductive Technologies Drives Preimplantation Genetic Testing Market Growth
The rising use of assisted reproductive technology (ART) forms one of the major factors contributing to the expansion of the PGT market. The growing incidence of infertility on account of delayed parenting, change in lifestyle choices, obesity, and reproductive diseases has resulted in more couples seeking treatment through in vitro fertilization (IVF). PGT has emerged as an important part of IVF through its ability to identify any chromosomal aberrations, single-gene disorders, and structural chromosome rearrangements prior to embryo transfer. It helps in improving embryo selection, enhances implantation rates, decreases the risk of spontaneous miscarriages, and reduces chances of transmitting hereditary diseases to offspring.
As per European Society of Human Reproduction and Embryology (ESHRE), more than 1 million ART treatment cycles are performed annually across Europe, highlighting the growing adoption of assisted reproductive technologies and the increasing need for advanced embryo genetic screening. Additionally, continuous developments in the fields of NGS and PCR technologies have resulted in enhanced precision and speed of PGT. Moreover, the awareness levels about reproductive genetics along with the expansion of fertility clinics and favorable regulations in certain nations are driving the uptake of PGT services. It is anticipated that the increase in the number of IVF cycles and the need for customized reproductive health services will drive the Preimplantation Genetic Testing Market over the coming years.
The Global Preimplantation Genetic Testing Market is segmented on the basis of Product, Application, End User, Technology, and Region.
Based on Preimplantation Genetic Testing Market, By Test Type, Preimplantation Genetic Testing for Aneuploidy Testing Services held the largest market share on account of their extensive usage during IVF treatment process in order to detect any anomalies in chromosomes. Such a genetic test increases the chances of implantation, lowers risks of miscarriages, and increases chances of conception especially in case of older women. Moreover, increased use of next-generation sequencing technology has increased the efficiency and accuracy of PGT-A testing services. For example, in May 2026, GenEmbryomics Limited introduced XGEN PGT-X(TM), which is the world's first clinical grade whole genome preimplantation genetic testing solution used in IVF embryos. It was made available through the company's Early Access Partner Program in order to provide comprehensive embryo-genome sequencing at an affordable price. Furthermore, PGT-M (Preimplantation Genetic Testing for Monogenic Disorders) Testing Services will experience high growth in the future on account of growing number of genetic testings for the screening of inherited disorders prior to embryo implantation.
Based on Application, IVF Embryo Selection accounts for the largest market share owing to the increasing number of IVF procedures worldwide and the growing emphasis on improving pregnancy success rates. Genetic Disorder Screening, Recurrent Pregnancy Loss Prevention, and Advanced Fertility Planning are also witnessing increased adoption as reproductive genetics becomes more integrated into fertility care. Based on End User, Fertility Clinics dominate the market due to the availability of specialized IVF laboratories, advanced embryo biopsy capabilities, and integrated genetic testing services. Based on Technology, Next Generation Sequencing (NGS) holds the largest market share owing to its high accuracy, scalability, and ability to simultaneously detect chromosomal abnormalities and genetic mutations, making it the preferred technology for modern preimplantation genetic testing.
Preimplantation Genetic Testing Market- Geographical Insights
Regarding the Preimplantation Genetic Testing (PGT) Market, North America occupied the largest market share due to the high adoption rate of Assisted Reproductive Technologies (ART), advanced genetic testing facilities, and the presence of prominent fertility clinics and reproductive genetics laboratories in the region. Further contributing factors are an increased understanding of genetic disorders, increasing age of mothers, and the increasing adoption of next-generation sequencing (NGS) based embryo screening for in vitro fertilization (IVF). The Centers for Disease Control and Prevention (CDC) reports that the United States is consistently performing high number of ART procedures every year due to persistent demand for IVF treatment. The CDC's National ART Surveillance System (NASS) collects data every year from about 500 fertility clinics in the U.S. It reported that about 435,426 ART cycles were performed in 2022. An increase in the number of ART procedures performed has resulted in the increasing use of PGT as part of the process, thus making North America the leading region in the market globally.
Europe is another major market due to the existence of established networks for fertility treatments, supportive regulatory environments in many countries, and ongoing technological developments in reproductive genetics. There has been an increase in the number of cases where IVF and embryo screening treatments have been used, especially in countries such as Spain, UK, Italy, and Denmark. More than one million ART treatment cycles are performed annually in Europe each year, which demonstrates that there is increased demand for IVF treatment and advanced genetic testing, which include PGT-A, PGT-M, and PGT-SR. The increasing adoption of NGS testing in fertility clinics is likely to further boost market growth in the region.
The Competitive landscape of the Preimplantation Genetic Testing (PGT) Market consist of the presence of specialized reproductive genetics laboratories, molecular diagnostics firms, and ART solution providers who compete by virtue of innovation in technology, expansion of their labs, and collaborative efforts. The major players include Vitrolife Group (Igenomix), CooperGenomics, Thermo Fisher Scientific Inc., Illumina, Inc., Natera, Inc., Fulgent Genetics, Genea Biomedx, Invitae Corporation, Eurofins Scientific, and Laboratory Corporation of America Holdings (Labcorp). These firms are developing NGS-based preimplantation genetic testing products, automated workflows, and larger laboratories for improving the efficiency and speed of the process. Firms are also focusing on the expansion of global laboratory networks, collaborations with fertility clinics, and use of genomic technology in IVF. This is expected to increase competition in the global Preimplantation Genetic Testing Market.
In April 2024, GenEmbryomics Limited and Progenesis Inc. entered into a strategic partnership to expand access to advanced preimplantation genetic testing for IVF patients. The collaboration combined Progenesis' laboratory capabilities with GenEmbryomics' Panacea-GenomeScreen(TM) PGT-WGS technology, enabling comprehensive whole-genome embryo screening and advancing genetic testing solutions in reproductive medicine.